Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Raised by Franklin Resources Inc.

Franklin Resources Inc. lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,118,688 shares of the specialty pharmaceutical company’s stock after acquiring an additional 48,708 shares during the quarter. Franklin Resources Inc. owned approximately 1.85% of Jazz Pharmaceuticals worth $124,208,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Synovus Financial Corp lifted its position in shares of Jazz Pharmaceuticals by 2.4% in the 3rd quarter. Synovus Financial Corp now owns 19,106 shares of the specialty pharmaceutical company’s stock valued at $2,129,000 after acquiring an additional 451 shares in the last quarter. Sanctuary Advisors LLC lifted its position in Jazz Pharmaceuticals by 502.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company’s stock worth $1,310,000 after buying an additional 9,804 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after buying an additional 165 shares in the last quarter. MidWestOne Financial Group Inc. lifted its position in Jazz Pharmaceuticals by 5.4% in the 3rd quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock worth $2,458,000 after buying an additional 1,134 shares in the last quarter. Finally, Barclays PLC lifted its position in Jazz Pharmaceuticals by 19.1% in the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock worth $4,369,000 after buying an additional 6,289 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $123.04 on Monday. The company has a 50-day moving average of $117.39 and a 200-day moving average of $112.22. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 1.02 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Wall Street Analyst Weigh In

JAZZ has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Piper Sandler restated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,753 shares of company stock valued at $816,289. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.